Welcome to the all-new Vetlearn

  • Vetlearn is getting a new home. Starting this fall,
    Vetlearn becomes part of the NAVC VetFolio family.

    You'll have access to the entire Compendium and
    Veterinary Technician archives and get to explore
    even more ways to learn and earn CE by becoming
    a VetFolio subscriber. Subscriber benefits:
  • Over 500 hours of interactive CE Videos
  • An engaging new Community for tough cases
    and networking
  • Three years of NAVC Conference Proceedings
  • All-new articles (CE and other topics) for the entire
    healthcare team

To access Vetlearn, you must first sign in or register.


  • Registration for new subscribers will open in September 2014!
  • Watch for additional exciting news coming soon!
Become a Member

Reference Desk February 2012

Pfizer and France's Hippolia Foundation Join Forces to Advance Science for Equine Health

    Strategic Partnership to Focus on Research and Education

    NORMANDY, France—Pfizer Animal Health and The Hippolia Foundation has announced the formation of a strategic partnership to advance equine health through research and educational programs.

    The Hippolia Foundation—a network of leading French equine institutions together with international partners—will collaborate with Pfizer to accelerate advancement in innovation on the diagnosis, treatment and prevention of equine disease. The Hippolia partner organizations and Pfizer are initially investing more than $5 million over three years.

    “This is an excellent example of a public/private initiative to advance our scientific knowledge and improve animal health and welfare,” said Pierre Lekeux, President, The Hippolia Foundation. 

    The two principal areas of collaboration to be developed between Pfizer and The Hippolia Foundation will focus on respiratory disorders and on infectious diseases.

    “This is a particularly synergistic partnership,” said Alejandro Bernal, Area President, Pfizer Animal Health, Europe, Africa and Middle East.

    “Together, The Hippolia Foundation and Pfizer have created a partnership based on what is today the largest equine research network worldwide. Both parties will benefit from the combined expertise and resources in the interests of accelerating pioneering equine research.”

    Pfizer Animal Health has a broad and leading portfolio of parasiticides, pharmaceuticals, and core and speciality vaccines. The latter group includes Equip for Flu, Tetanus and EHV as well as vaccines which address emerging disease—importantly, West Nile virus.

    In November 2011, the company opened a new global Equine Research Center at its worldwide veterinary medicine research and development headquarters in greater Kalamazoo, Michigan. Pfizer Animal Health is dedicated to providing comprehensive solutions for equine health, including an integrated offer of vaccines, therapeutics, diagnostics, practice management and services.

    Founded in 2011 and located in Normandy—at the center of one of Europe’s most recognised regions for competition horses—The Hippolia Foundation supports and promotes the development of research programs, training, and services at an international level, particularly on issues of health, welfare, and performance in horses.

    The Normandy site has established a reputation as a world-class facility undertaking leading-edge research on racehorses (thoroughbred and standardbred) but also on sport horses. The Hippolia Foundation also has existing partnerships with hospitals, and it is expected that its research could possibly have comparative translational aspects that would benefit human health as well as equine.

    About Pfizer Animal Health

    Pfizer Animal Health, a business unit of Pfizer Inc, is a world leader in the discovery, development, and manufacture of innovative animal health vaccines, medicines, and diagnostic products. To learn more, visit www.pfizeranimalhealth.com.

    Source: Pfizer Animal Health


    Did you know... Hand hygiene is a simple and effective means of reducing transmission of methicillin-resistant Staphylococcus aureus.Read More

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More